1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
56 A Phase 2 Exploratory Study of Intravenous Cetirizine Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions in Patients With Breast Cancer and Other Malignancies
5 A Prospective, Double-Blinded, Randomized Controlled Trial Comparing the Intraoperative Injection of Technetium Tc 99m Tilmanocept With Technetium Tc 99m Sulfur Colloid in Breast Cancer Lymphatic Mapping
9 Comparison of Immediate Breast Reconstruction Outcomes in Patients With and Without Prior Breast Cosmetic Surgical Procedures
11 Do Breast Surgeons Play an Important Role in a Clinic for Benign Breast Disease?
12 Caseload of Rural General Surgeons: A Focus on Breast Surgery
17 TiP The Treatment of Breast Cancer With Percutaneous Thermal Ablation: A Phase 2 Screening Trial
18 The Impact on Management and Outcomes of Benign and High-Risk Breast Lesions After the Introduction of Vacuum-Assisted Excision
20 Assessment of Textbook Oncologic Outcomes Following Modified Radical Mastectomy for Invasive Ductal Carcinoma: A Review of the 2004-2017 National Cancer Database
27 Radar Reflector Localization of Peripheral Nonpalpable Lesions During Skin-Sparing and Nipple-Sparing Mastectomy: A Novel Application Using the IDEAL Framework
40 Objective Comparison of Postoperative Activity After Sentinel Lymph Node Biopsy vs Axillary Node Clearance Using Wearable Activity Monitors
41 Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Test Results Are Consistent Among Pre and Postmenopausal Patients
49 Registry Study of a Nonpalpable Verifiable Filament Marker of the Breast Tumor Bed
50 Breast Tissue Differentiation With High Wavenumber Raman Spectroscopy for Future Intraoperative Margin Analysis
51 Institution Case Study Series With Tc-99m Tilmanocept for Efficiencies in Sentinel Lymph Node Biopsy
4 Incidental Breast Cancer on Chest CT: Is the Radiology Report Enough?
